No Data
No Data
Bright Minds Rally Ends as Psychedelic Stocks Extend Volatility
Leerink Partners Initiates Mind Medicine(MNMD.US) With Buy Rating, Announces Target Price $20
Mind Medicine: A Strong Buy on Financial Health and Growth Prospects
Mind Medicine Assumed With an Outperform at Leerink
Mind Medicine's Chief Medical Officer Sells Shares Worth Over $41,000
Express News | Mind Medicine (MindMed) Inc : Canaccord Genuity Cuts Target Price to $14 From $16
No Data
No Data